Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 3
2016 6
2017 4
2018 5
2019 4
2020 5
2021 4
2022 8
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
2018 update of the EULAR recommendations for the management of Behçet's syndrome.
Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kötter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H. Hatemi G, et al. Among authors: ozguler y. Ann Rheum Dis. 2018 Jun;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225. Epub 2018 Apr 6. Ann Rheum Dis. 2018. PMID: 29625968
Epidemiology of systemic vasculitis.
Ozguler Y, Esatoglu SN, Hatemi G. Ozguler Y, et al. Curr Opin Rheumatol. 2024 Jan 1;36(1):21-26. doi: 10.1097/BOR.0000000000000983. Epub 2023 Oct 5. Curr Opin Rheumatol. 2024. PMID: 37800639 Review.
Current pharmacological solutions for Behçet's syndrome.
Ozguler Y, Esatoglu SN, Hatemi G. Ozguler Y, et al. Expert Opin Pharmacother. 2023 Feb;24(2):221-231. doi: 10.1080/14656566.2022.2155047. Epub 2022 Dec 15. Expert Opin Pharmacother. 2023. PMID: 36458741 Review.
Management of Behçet's syndrome.
Ozguler Y, Hatemi G. Ozguler Y, et al. Curr Opin Rheumatol. 2016 Jan;28(1):45-50. doi: 10.1097/BOR.0000000000000231. Curr Opin Rheumatol. 2016. PMID: 26555450 Review.
Recent Insights into the Management of Behçet Syndrome.
Ozguler Y, Ozdede A, Hatemi G. Ozguler Y, et al. J Inflamm Res. 2021 Jul 20;14:3429-3441. doi: 10.2147/JIR.S285400. eCollection 2021. J Inflamm Res. 2021. PMID: 34321904 Free PMC article. Review.
Infliximab for vascular involvement in Behçet's syndrome.
Hatemi G, Tukek NB, Esatoglu SN, Ozguler Y, Taflan SS, Uygunoglu U, Melikoglu M, Ugurlu S, Fresko I, Siva A, Kutlubay Z, Yurdakul S, Yazici H, Hamuryudan V. Hatemi G, et al. Among authors: ozguler y. Clin Immunol. 2023 Aug;253:109682. doi: 10.1016/j.clim.2023.109682. Epub 2023 Jun 28. Clin Immunol. 2023. PMID: 37385325
Management of Behçet's syndrome.
Ozguler Y, Hatemi G, Yazici H. Ozguler Y, et al. Curr Opin Rheumatol. 2014 May;26(3):285-91. doi: 10.1097/BOR.0000000000000050. Curr Opin Rheumatol. 2014. PMID: 24614278 Review.
Inadequate reporting of enrolled patient and study site characteristics, and inter-study site differences in randomized controlled trials: A systematic review in six leading medicine journals.
Yurdakul S, Ayan G, Ozguler Y, Hatemi G, Ugurlu S, Seyahi E, Yazici H. Yurdakul S, et al. Among authors: ozguler y. Eur J Intern Med. 2017 Jan;37:e34-e36. doi: 10.1016/j.ejim.2016.09.019. Epub 2016 Oct 5. Eur J Intern Med. 2017. PMID: 27720299 Review. No abstract available.
39 results